|
1
|
Wang Z, Hao G, Zhang L, Chen Z, Wang X,
Guo M, Tian Y, Shao L and Zhu M: Central systolic blood pressure is
associated with ethnicity and cardiovascular disease risk factors
in Chinese middle-aged population. Eur J Prev Cardiol. Mar
27–2015.Epub ahead of print. View Article : Google Scholar
|
|
2
|
Cano-Gutierrez C, Reyes-Ortiz CA,
Samper-Ternent R, Gélvez-Rueda JS and Borda MG: Prevalence and
factors associated to hypertension among older adults in Bogotá,
Colombia. J Aging Health. Mar 24–2015.Epub ahead of print.
View Article : Google Scholar
|
|
3
|
Mahn JJ, Dubey E, Brody A, Welch R,
Zalenski R, Flack JM, Ference B and Levy PD: Test characteristics
of electrocardiography for detection of left ventricular
hypertrophy in asymptomatic emergency department patients with
hypertension. Acad Emerg Med. 21:996–1002. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luft FC: Present status of genetic
mechanisms in hypertension. Med Clin North Am. 88:1–18. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kern G, Mair SM, Noppert SJ, Jennings P,
Schramek H, Rudnicki M, Mueller GA, Mayer G and Koppelstaetter C:
Tacrolimus increases Nox4 expression in human renal fibroblasts and
induces fibrosis-related genes by aberrant TGF-beta receptor
signalling. PLoS One. 9:e963772014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pandey VG, Jain S, Rana A, Puri N, Arudra
SK, Mopidevi B, Kaw M, Nasjletti A and Kumar A: Dexamethasone
promotes hypertension by allele-specific regulation of the human
angioten-sinogen gene. J Biol Chem. 290:5749–5758. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qi Y, Zhang K, Wu Y, Xu Z, Yong QC, Kumar
R, Baker KM, Zhu Q, Chen S and Guo S: Novel mechanism of blood
pressure regulation by forkhead box class O1-mediated
transcriptional control of hepatic angiotensinogen. Hypertension.
64:1131–1140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alves M, Souza e Silva NA, Salis LH,
Pereira Bde B, Godoy PH, Nascimento EM and Oliveira JM: Survival
and predictive factors of lethality in hemodialysis: D/I
polymorphism of the angio-tensin I-converting enzyme and of the
angiotensinogen M235T genes. Arq Bras Cardiol. 103:209–219.
2014.PubMed/NCBI
|
|
9
|
Zhu X, Chang YP, Yan D, Weder A, Cooper R,
Luke A, Kan D and Chakravarti A: Associations between hypertension
and genes in the reninangiotensin system. Hypertension.
41:1027–1034. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kolder IC, Michels M, Christiaans I, Ten
Cate FJ, Majoor-Krakauer D, Danser AH, Lekanne Deprez RH, Tanck M,
Wilde AA, Bezzina CR, et al: The role of
renin-angiotensin-aldo-sterone system polymorphisms in phenotypic
expression of MYBPC3-related hypertrophic cardiomyopathy. Eur J Hum
Genet. 20:1071–1077. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu P, Wang Y, Sterner-Kock A, Bader M,
Schultheiss HP and Walther T: Excessive hypertension and end-organ
damage in a transgenic mouse line carrying the rat angiotensinogen
gene. J Cardiovasc Pharmacol. 53:38–43. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Makino N, Sugano M, Ohtsuka S and Sawada
S: Intravenous injection with antisense oligodeoxynucleotides
against angioten-sinogen decreases blood pressure in spontaneously
hypertensive rats. Hypertension. 31:1166–1170. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Caulfield M, Lavender P, Farrall M, Munroe
P, Lawson M, Turner P and Clark AJ: Linkage of the angiotensinogen
gene to essential hypertension. N Engl J Med. 330:1629–1633. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Feng PF, Liu Y and Qin NP: Effect of sanwu
hypotensive decoction on blood pressure and lymphokine activated
killer cell in patient of primary hypertension and spontaneously
hypotensive rats. Zhongguo Zhong Xi Yi Jie He Za Zhi. 21:342–345.
2001.
|
|
15
|
Pinto YM, Paul M and Ganten D: Lessons
from rat models of hypertension: From Goldblatt to genetic
engineering. Cardiovasc Res. 39:77–88. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wright JW, Mizutani S, Murray CE, Amir HZ
and Harding JW: Aminopeptidase-induced elevations and reductions in
blood pressure in the spontaneously hypertensive rat. J Hypertens.
8:969–974. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lemmer B, Mattes A, Böhm M and Ganten D:
Circadian blood pressure variation in transgenic hypertensive rats.
Hypertension. 22:97–101. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee RM: Structural alterations of blood
vessels in hypertensive rats. Can J Physiol Pharmacol.
65:1528–1535. 1987. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rippe B, Lundin S and Folkow B: Plasma
volume, blood volume and transcapillary escape rate (TER) of
albumin in young spontaneously hypertensive rats (SHR) as compared
with normotensive controls (NCR). Clin Exp Hypertens. 1:39–50.
1978. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Andresen MC, Krauhs JM and Brown AM:
Relationship of aortic wall and baroreceptor properties during
development in normotensive and spontaneously hypertensive rats.
Circ Res. 43:728–738. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xi-Ye Fang: Medical Experimental Zoology.
1st edition. People's Medical Publishing House; Beijing: pp.
p1211995
|
|
22
|
Wakui H, Tamura K, Masuda S, Tsurumi-Ikeya
Y, Fujita M, Maeda A, Ohsawa M, Azushima K, Uneda K, Matsuda M, et
al: Enhanced angiotensin receptor-associated protein in renal
tubule suppresses angiotensin-dependent hypertension. Hypertension.
61:1203–1210. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nabeshima Y, Tazuma S, Kanno K, Hyogo H
and Chayama K: Deletion of angiotensin II type I receptor reduces
hepatic steatosis. J Hepatol. 50:1226–1235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yue H, Li W, Desnoyer R and Karnik SS:
Role of nuclear unphos-phorylated STAT3 in angiotensin II type 1
receptor-induced cardiac hypertrophy. Cardiovasc Res. 85:90–99.
2010. View Article : Google Scholar
|
|
25
|
Chen X, Qiu Z, Yang S, Ding D, Chen F,
Zhou Y, Wang M, Lin J, Yu X, Zhou Z, et al: Effectiveness and
safety of a therapeutic vaccine against angiotensin II receptor
type 1 in hypertensive animals. Hypertension. 61:408–416. 2013.
View Article : Google Scholar
|
|
26
|
He J, Bian Y, Gao F, Li M, Qiu L, Wu W,
Zhou H, Liu G and Xiao C: RNA interference targeting the ACE gene
reduced blood pressure and improved myocardial remodelling in SHRs.
Clin Sci (Lond). 116:249–255. 2009. View Article : Google Scholar
|
|
27
|
Lu P, Yuan L, Wang Y, Du Q and Sheng J:
Effect of GPE-AGT nanoparticle shRNA transfection system mediated
RNAi on early atherosclerotic lesion. Int J Clin Exp Pathol.
5:698–706. 2012.PubMed/NCBI
|
|
28
|
Gong H, Liu CM, Liu DP and Liang CC: The
role of small RNAs in human diseases: Potential troublemaker and
therapeutic tools. Med Res Rev. 25:361–381. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park TG, Jeong JH and Kim SW: Current
status of polymeric gene delivery systems. Adv Drug Deliv Rev.
58:467–486. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Srinivas R, Samanta S and Chaudhuri A:
Cationic amphiphiles: Promising carriers of genetic materials in
gene therapy. Chem Soc Rev. 38:3326–3338. 2009. View Article : Google Scholar
|
|
31
|
Mintzer MA and Simanek EE: Nonviral
vectors for gene delivery. Chem Rev. 109:259–302. 2009. View Article : Google Scholar
|
|
32
|
Yu H and Wagner E: Bioresponsive polymers
for nonviral gene delivery. Curr Opin Mol Ther. 11:165–178.
2009.PubMed/NCBI
|
|
33
|
Wang YQ, Su J, Wu F, Lu P, Yuan LF, Yuan
WE, Sheng J and Jin T: Biscarbamate cross-linked polyethylenimine
derivative with low molecular weight, low cytotoxicity, and high
efficiency for gene delivery. Int J Nanomedicine. 7:693–704.
2012.PubMed/NCBI
|
|
34
|
Lu P, Yuan L, Wang Y, Du Q and Sheng J:
Effect of GPE-AGT nanoparticle shRNA transfection system mediated
RNAi on early atherosclerotic lesion. Int J Clin Exp Pathol.
5:698–706. 2012.PubMed/NCBI
|
|
35
|
Wang Y, Su J, Cai W, Lu P, Yuan L, Jin T,
Chen S and Sheng J: Hepatocyte-targeting gene transfer mediated by
galactosylated poly(ethylene glycol)-graft-polyethylenimine
derivative. Drug Des Devel Ther. 7:211–221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang X, Gao Y, Dong J, Wang S, Yao B,
Zhang J, Hu S, Xu X, Zuo H, Wang L, et al: The compound Chinese
medicine 'Kang Fu Ling' protects against high power
microwave-induced myocardial injury. PLoS One. 9:e1015322014.
View Article : Google Scholar
|
|
37
|
Silvani A, Bastianini S, Berteotti C,
Cenacchi G, Leone O, Lo Martire V, Papa V and Zoccoli G: Sleep and
cardiovascular phenotype in middle-aged hypocretin-deficient
narcoleptic mice. J Sleep Res. 23:98–106. 2014. View Article : Google Scholar
|
|
38
|
Li D, Lv J, Liu F, Liu P, Yang X, Feng Y,
Chen G and Hao M: Hypertension burden and control in mainland
China: Analysis of nationwide data 2003–2012. Int J Cardiol.
184:637–644. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Khandelia P, Yap K and Makeyev EV:
Streamlined platform for short hairpin RNA interference and
transgenesis in cultured mammalian cells. Proc Natl Acad Sci USA.
108:12799–12804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Maillard PV, Ciaudo C, Marchais A, Li Y,
Jay F, Ding SW and Voinnet O: Antiviral RNA interference in
mammalian cells. Science. 342:235–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Y, Lu J, Han Y, Fan X and Ding SW: RNA
interference functions as an antiviral immunity mechanism in
mammals. Science. 342:231–234. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lebedev TD, Spirin PV and Prassolov VS:
Transfer and expression of small interfering RNAs in mammalian
cells using lentiviral vectors. Acta Naturae. 5:7–18.
2013.PubMed/NCBI
|
|
43
|
Hannon GJ: RNA interference. Nature.
418:244–251. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pare JM, LaPointe P and Hobman TC: Hsp90
cochaperones p23 and FKBP4 physically interact with hAgo2 and
activate RNA interference-mediated silencing in mammalian cells.
Mol Biol Cell. 24:2303–2310. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Paddison PJ: RNA interference in mammalian
cell systems. Curr Top Microbiol Immunol. 320:1–19. 2008.PubMed/NCBI
|
|
46
|
Dalmay T: MicroRNAs and cancer. J Intern
Med. 263:366–375. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ohkumo T, Masutani C, Eki T and Hanaoka F:
Use of RNAi in C. elegans. Methods Mol Biol. 442:129–137. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Huang DD: The potential of RNA
interference-based therapies for viral infections. Curr HIV/AIDS
Rep. 5:33–39. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen Y, Cheng G and Mahato RI: RNAi for
treating hepatitis B viral infection. Pharm Res. 25:72–86. 2008.
View Article : Google Scholar :
|
|
50
|
Volarevic M, Smolic R, Wu CH and Wu GY:
Potential role of RNAi in the treatment of HCV infection. Expert
Rev Anti Infect Ther. 5:823–831. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Singh SK: RNA interference and its
therapeutic potential against HIV infection. Expert Opin Biol Ther.
8:449–461. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ying SY and Lin SL: Current perspectives
in intronic micro RNAs (miRNAs). J Biomed Sci. 13:5–15. 2006.
View Article : Google Scholar
|
|
53
|
Chen D, Hazelwood L, Walker LL, Oldfield
BJ, McKinley MJ and Allen AM: Changes in angiotensin type 1
receptor binding and angiotensin-induced pressor responses in the
rostral ventrolateral medulla of angiotensinogen knockout mice. Am
J Physiol Regul Integr Comp Physiol. 298:R411–R418. 2010.
View Article : Google Scholar
|
